NICE backs Lilly's weekly insulin Onswik for NHS use ahead of UK approval

21 August 2026

The UK's cost-effectiveness watchdog has recommended US pharma major Eli Lilly's (NYSE: LLY) once-weekly basal insulin Onswik (insulin efsitora alfa) for adults with type 2 diabetes on the National Health Service, even though the product has yet to be licensed in the country.

The National Institute for Health and Care Excellence (NICE) published final draft guidance on August 20 covering England and Wales. Its recommendation only takes effect once the Medicines and Healthcare products Regulatory Agency (MHRA) grants a marketing authorization. An appeal window is now open, with final guidance expected by September 10.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK